Torcetrapib was a drug being developed to treat hypercholesterolemia and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and the study drug. Torcetrapib acts by inhibiting cholesterylester transfer protein , which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins . Inhibition of this process results in higher...